Results demonstrates that use of KneeKG in patients with osteoarthritis reduces pain, improves patient quality of life, and may reduce need for unnecessary surgery.
Montreal, Quebec (October 1st, 2019) Today, Emovi, Inc. announces positive results from a randomized, controlled trial involving KneeKG™, Emovi’s flagship medical device and the first device that enables healthcare professionals to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. The results indicate that integrating data from an objective biomechanical evaluation using KneeKG into the management of knee osteoarthritis patients, can significantly reduce patients’ pain while improving their function and satisfaction levels.
Emovi’s clinical study has been accepted for publication by Postgraduate Medicine, a peer-reviewed medical journal established by Charles Mayo MD, founder of the Mayo Clinic. The journal publishes research which supports primary care physicians in solving clinical problems and improving patient care.
About the Trial
In the cluster randomized controlled trial, primary care clinics were randomized into three groups, as outlined in Figure 1 below:
Of the 894 patients referred from 87 clinics, 449 completed the study. At the six-month follow-up appointments, patients in Group 2 and Group 3, the KneeKG groups, reported statistically significant improvement in symptoms, pain, and activities of daily living subscales. The study also demonstrated a higher engagement of patients in their care in Group 2 and 3.
This pivotal study demonstrates that KneeKG enhances physicians’ capability and knowledge base to immediately pinpoint functional deficits that correlates to the patient’s knee pain. The Knee Kinesiography by KneeKG enables the physician and other healthcare professionals to determine the most appropriate patient specific care to achieve better outcomes and restore optimal knee function which could potentially delay the need for knee replacement as suggested by a previous study.
“These study findings are a huge win for the millions of people suffering from knee pain and for healthcare professionals,” said Michelle Laflamme, CEO of Emovi. “KneeKG is a new level of orthopedic innovation providing real time, quantifiable data that objectively and accurately assesses dynamic knee function. and these results position the device as a solution to improve the current standard of care
.It is a non-invasive technology that can identify the true biomechanical deficits impacting knee (dys)function which can guide the development of a targeted, patient specific, non-surgical treatment plan for knee OA that reduces patient pain and improve function of daily activities.”
Osteoarthritis (OA) is the most common joint disorder in many countries, affecting for example 13.9% of adults 25 years and older and 33.6% of people 65 years and older in the United States. In Canada, it affects more Canadians than all other forms of arthritis combined.
KneeKG is the first in-clinic device that meets the global need for measuring knee function with objective and quantifiable data associated with mechanical knee markers and functional deficiencies.
KneeKG enables the accurate assessment of patients’ knees in 3D while the patient is moving and weight-bearing. The exam is performed while the patient is walking on a treadmill. A report with explanations is sent to the doctor. KneeKG is to the Knee what the electrocardiogram is to the heart. By providing functional information to doctors with a higher correlation to symptoms and at a fraction of the cost of high-tech scans such as MRIs, the KneeKG allows doctors to significantly improve patients’ quality of life, pain and functional limitations, revolutionizing existing knee assessment.
About Emovi Inc.
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore patient quality of life. In partnership with the Quebec university research community, including the CRCHUM, École de technologie supérieure (ÉTS) and TELUQ, Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive license to commercialize the KneeKG worldwide.